Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals of the Week: Stada/Grunenthal, Stada/Spirig, Shire/Sangamo

Executive Summary

While 2012 promises to be a lucrative for generic drug companies, they now face their own reverse patent cliff. Some, therefore, are looking to diversify into branded products.

You may also be interested in...



Merck KGaA Draws A Line Under “Old” R&D, Now Seeks More Deals

Germany’s Merck KGaA has streamlined its R&D pipeline, concentrating on immuno-oncology, early-stage compounds and collaborative efforts with partners, and discontinuing expensive late-stage products that were going nowhere.

Shire Buys FerroKin BioSciences To Further Hematology Strategy

Shire gains an iron chelator in Phase II development in exchange for $100 million upfront and post-closing milestones of $225 million.

Genzyme Restart Won’t Hobble Shire’s 2012 Prospects, Shire’s Gregoire Says

Shire expects only a gradual pick up of competitive pressure from Genzyme's resumption of Fabrazyme manufacturing, with the double-digit growth of revenues in 2011 set to be replicated in 2012.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS054165

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel